Rolapitant: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Rolapitant. Educational only — not medical advice.

Labeled uses

VARUBI® is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

Source: FDA labeling via NIH DailyMed (set 8670c3cf…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.